Reports Wednesday, July 29, 2026, before the U.S. market opens
BSX enters 2Q earnings with expectations reset sharply lower, but with the bar now relatively manageable. The central question is not whether Boston Scientific can meet the quarter’s 5%–7% organic-sales-growth and $0.82–$0.84 adjusted EPS guide; it is whether management can credibly demonstrate that the Q2 slowdown represents a trough rather than the beginning of a more durable reset in its two most important growth franchises: electrophysiology (EP/FARAPULSE) and WATCHMAN.
The Street is reportedly modeling 5.3% organic revenue growth and $0.83 of adjusted EPS—essentially the low half/midpoint of management’s range. That leaves room for a modest beat, but the stock’s reaction will likely depend far more on the full-year outlook, segment-level trends, and management’s confidence in a 2027 reacceleration.
| Metric | 2Q26 company guide | Street expectation | 2Q25 actual |
|---|---|---|---|
| Organic sales growth | 5.0%–7.0% | 5.3% | 17.4% |
| Reported sales growth | 5.5%–7.5% | — | 22.8% |
| Implied reported revenue | ~$5.34B–$5.44B | — | $5.06B |
| Adjusted EPS | $0.82–$0.84 | $0.83 | $0.75 |
The earnings comparison is difficult: 2Q25 included 17.4% organic growth, driven by exceptional Cardiovascular growth and a rapidly scaling FARAPULSE platform. The 2026 guide therefore reflects both tougher comparisons and specific execution issues rather than a broad deterioration in underlying procedure markets.
BSX’s shares closed at $46.07 on July 28, down roughly 29% from the $64.87 close immediately following 1Q earnings on April 22. That decline suggests investors already recognize the growth reset, although expectations may still be sensitive to any further full-year de-risking.
EP is the biggest debate. In 1Q, EP grew 22% organically, but management reduced its full-year EP outlook to approximately 10% growth, with U.S. growth expected in the mid-single digits. The issue is not category demand; it is rising competition and more share loss than BSX had anticipated in pulsed-field ablation.
Investors should focus on:
WATCHMAN grew 19% organically in 1Q, but management lowered its 2026 outlook to mid-teens globally. The key issue is a weakening standalone business, partly offset by growth in concomitant procedures performed alongside AF ablations.
Management attributed the slowdown to hospital-capacity constraints, changing physician workflow, prioritization of other procedures, reimbursement dynamics, and a shift in activity toward EP-led concomitant procedures. The favorable CHAMPION-AF data supports the long-term clinical proposition, but its translation into labeling, guidelines, coverage, and actual procedure growth will take time.
For 2Q, investors should look for:
A stable WATCHMAN result could be enough for the stock; another material deceleration would likely renew concerns about the durability of one of BSX’s highest-value growth drivers.
Urology grew just 0.5% organically in 1Q, pressured by China volume-based procurement effects in stone management, product gaps, and disruption within the sacral-neuromodulation commercial organization. Management has hired and trained a significant number of new commercial and clinical personnel and expects sequential improvement.
Endoscopy was healthier, growing 6.8% organically in 1Q, though management flagged supply constraints around AXIOS and other transient disruptions in Q2.
The read-through:
At the midpoint, 2Q adjusted EPS of $0.83 would be up about 11% year over year despite a sharp revenue-growth deceleration. That puts the focus on margin execution.
In 1Q, adjusted gross margin declined 100 basis points year over year to 70.5%, reflecting tariffs and POLARx discontinuation-related inventory charges. Management nevertheless maintained its expectation for 50–75 basis points of full-year adjusted operating-margin expansion, largely through operating-expense controls and organizational efficiency efforts.
The added complication is BSX’s restructuring announcement on July 27, 2026. The company approved a program expected to generate:
The program runs through 2029 and includes supply-chain optimization, manufacturing-line transfers, functional transformation, and organizational changes. It is strategically constructive if management can protect R&D, commercial execution, and product supply—but it raises near-term questions around cash usage, implementation risk, and the quality of reported versus adjusted earnings.
Key implication: Investors should separate the near-term non-GAAP EPS effect from the more important question of whether the restructuring makes the long-term margin algorithm more credible.
BSX’s current full-year framework is:
Management characterized 2Q as the toughest quarter of the year and previously implied a modest recovery thereafter, toward roughly 7% growth in the second half. As a result:
BSX reports organic growth toward the upper half of its 5%–7% range, meets or exceeds $0.84 adjusted EPS, confirms stabilization in U.S. EP and standalone WATCHMAN, and reiterates the full-year framework. With the shares substantially lower since April, a clean execution quarter could support a relief rally.
Organic growth lands near 5%–6%, adjusted EPS is around $0.83, and management maintains guidance but remains cautious on EP and WATCHMAN. This would validate the reset but may not be enough to drive a major rerating.
Organic growth misses the 5% floor, WATCHMAN standalone volumes remain weak, U.S. EP trends deteriorate further, or the company reduces its full-year growth or EPS range. The market is likely to view another cut as evidence that the 2026 issues are more structural than management has suggested.
Boston Scientific is balancing a substantial investment agenda with shareholder returns:
These moves reinforce management’s intent to remain aggressive in high-growth cardiovascular categories. But alongside the new restructuring program, they make cash deployment, leverage, transaction timing, and integration discipline important discussion points.
BSX remains a high-quality medtech franchise with leading positions in attractive procedure markets, a differentiated clinical pipeline, and meaningful long-term margin opportunity. However, this quarter is primarily a credibility and stabilization test.
A result near the low end of guidance can still work for the stock if it comes with tangible evidence that EP competition is manageable, WATCHMAN standalone trends are bottoming, Urology is improving, and the full-year guide is durable. Conversely, another reset would be especially damaging because management already framed 2Q as the trough quarter and positioned 2027 as the recovery year.